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Abstract 
The New Zealand Biotechnology sector is worthy of study for several reasons. While 
there is a large and growing international literature on economic aspects of 
biotechnology innovation these studies concentrate on the United States and Europe. 
The New Zealand biotechnology sector may be expected to develop along a different 
trajectory as a consequence of a markedly different set of initial and framework 
conditions. Government has indicated a strong interest in fostering innovation and 
aims to concentrate on selected areas where New Zealand may be able to develop a 
new comparative advantage. One such area is biotechnology, which would build on 
New Zealand’s existing comparative advantage in the primary sector (dairy, forestry, 
meat, wool and horticulture). This paper describes the preliminary results of an 
ongoing study that aims to fill some of the gaps in our knowledge of innovation 
processes in New Zealand while using the international literature as a benchmark. The 
paper focuses on the drivers of innovation in the biotechnology sector; the role of 
networks and other linkages; the role of government and industry, the role of human 
and venture capital, and data from patenting.  
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1. Introduction 
 
Modern biotechnology has the potential to transform large parts of the global 
economy and to have a major impact on the way we live. Its birth is usually traced 
back to the development of the recombinant DNA technique in 1973 and hybridoma 
technology in 1975 (Orsenigo, 1989, p. 37). The rapid pace and widespread impact of 
developments in biotechnology since that time has often been referred to as the 
biotechnological revolution. This has a number of features which make it quite 
distinct from the traditional model of technological revolutions1:  
First, whereas the traditional model is derived largely from the study of radical 
shifts in engineering knowledge …, the revolution in molecular biology 
represented a shift in the scientific knowledge base of an industry. Second, despite 
the sweeping nature of the molecular revolution, incumbent pharmaceutical 
companies have not been swept away by new entrants. Third, and relatedly the 
relationship between incumbents and entrants has entailed not only competition 
but also cooperation and the establishment of complex interactions between firms 
(Henderson, Orsenigo and Pisano, 1999, p. 268). 
Eliasson and Eliasson (1997, p. 141) add that: 
biotechnology originated in academia and therefore corresponds to the ideal 
concept of a science-based industry, …new discoveries … are almost always the  
result of a combination of different clusters of scientific know-how: in chemistry, 
molecular biology, cell biology, physiology, and toxicology, pharmacology… 
[and] failed experiments are a significant part of the total development costs in the 
industry. 
It is also interesting because of it’s markedly different effects on industry structure in 
different parts of the world. This contrasts with the standard view of scientific 
advance as creating a ‘free good’, which is universally available. 
 
There is a large and growing international literature on economic aspects of 
biotechnology innovation. Carlsson (1997) and his co-workers used the concept of 
technological systems to analyse the development, diffusion and utilization of 
technology in various fields of economic activity including the “pharmaceutical and 
biotechnological competence bloc” (Eliasson and Eliasson, 1997). Orsenigo (1989), 
McKelvey (1996), and others described and explained the emergence and 
development of the biotechnology industry within an evolutionary framework. Zucker 
and Darby (1996) and their co-workers produced a range of detailed studies on factors 
influencing the development of the modern biotechnology industry in the United 
States and Japan. They focussed particularly on the first 10 to 15 years of the biotech 
revolution when innovations were characterized by naturally excludable knowledge in 
the hands of only a few star scientists. They found that generation of biotech 
knowledge in a specific location was the principle determinant of the growth of the 
biotech industry in that area. 
                                                 
1 Some consider biotechnology to be the third revolution – the industrial and information technology 
(computer) revolutions being the first two. Biotechnology may also be viewed as a ‘technoeconomic 
paradigm’ e.g. steam power, electric power and computer technology 
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1.1 Aims of this Paper 
Our empirical knowledge of innovation processes and knowledge flows in New 
Zealand is embryonic. New Zealand has not undertaken innovation surveys 
comparable to those implemented in Europe and the OECD under the Community 
Innovation Survey (CIS), National Innovation System (OECD) and other projects. 
This paper describes the preliminary results of an ongoing study that aims to fill some 
of the gaps in our knowledge of innovation processes in New Zealand while using the 
international literature as a benchmark. The study will describe and analyse the 
innovation system for biotechnology in New Zealand focussing on the major actors 
(firms, research organisations, universities, government, overseas linkages) and the 
linkages among them (knowledge flows, financial flows, links with suppliers and 
customers, other linkages).  
 
This paper is divided into five sections. Section 2 describes New Zealand’s National 
System of Innovation, including a review of the effects of recent science reforms and 
the strength of the science base. Section 3 describes New Zealand’s biotechnology 
based sectors and the role of private industry, research organisations and the 
universities. Some of the factors affecting innovation in biotechnology in New 
Zealand are reviewed in Section 4. The paper closes with some concluding remarks 
on the current state of the biotechnology sector in New Zealand.  
 
The New Zealand Biotechnology sector is worthy of study for several reasons. While 
there is a large and growing international literature on economic aspects of 
biotechnology innovation, these studies concentrate on the United States and Europe 
and little has been written on New Zealand or similar countries e.g. Australia. The 
New Zealand biotechnology sector may be expected to develop along a different 
trajectory as a consequence of a markedly different set of initial and framework 
conditions2. New Zealand has a small open economy, which has been modified by an 
extensive set of institutional and economic reforms including transformation of the 
national science and technology system towards a more market driven model. 
Government has indicated a strong interest in fostering innovation and aims to 
concentrate on selected areas where New Zealand may be able to develop a new 
comparative advantage. One such area is biotechnology, which would build on New 
Zealand’s existing comparative advantage in the primary sector (dairy, forestry, meat, 
wool and horticulture). 
1.2 The Systems of Innovation Framework 
The current study uses the Systems of Innovation (SI) literature (Freeman, 1987; 
Lundvall, 1992; Nelson, 1993) as a theoretical framework. Central to this concept is 
the idea that the overall innovation performance of an economy depends not so much 
on how specific organisations perform but on how well they interact with each other. 
Systems of innovation have been analysed at several levels ranging from enterprise 
specific innovation systems, to local, national, regional and global systems of 
innovation. In focussing on a particular sector within the SI approach, this paper 
follows Metcalfe who explains the concept of sectoral innovation systems: 
                                                 
2 framework conditions of national, institutional and structural factors set the rules and range of 
opportunities for innovation (OECD, 1997, p. 31) 
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as a convenient middle ground which recognises that not all the influences on 
technical progress lie within the firm, and that an economy wide, aggregate, 
approach can make little sense of the diverse conditions in which different kinds 
of knowledge are accumulated (1998, p. 2). 
He suggests “the fundamental source of growth is innovation at the level of the firm 
and that it is this which underpins structural change within and between economic 
sectors”. He argues that there are major differences in the technical progress 
functions3 of different sectors that shape the overall pattern of growth. As a result the 
principal focus of empirical investigation should be at the sectoral level. Pavitt’s 
(1984) paper on sectoral patterns of technical change was an important precursor 
while the formal appearance of the Sectoral Innovation System (SIS) approach is 
generally traced back to Breschi and Malerba. They defined it as: 
that system (group) of firms active in developing and making a sector’s products 
and in generating and utilizing a sector’s technologies. Such a system of firms is 
related … through processes of interaction and cooperation in artefact-technology 
development and through processes of competition and selection in innovative 
and market activities (1997, p. 131). 
Carlsson and Stankiewicz (1991) had earlier developed the alternative concept of the 
Technological System (TS) as a network of vertically and horizontally connected 
agents and organisations; somewhat different to the SIS approach where the central 
actors are private firms and the focus is on competitive relationships among firms. 
The TS research theme led by Bo Carlsson was developed under a five-year research 
programme on Sweden’s Technological Systems and Future Development Potential. 
The programme includes theoretical studies of technological systems as well as 
empirical studies of factory automation (Carlsson, 1995), electronics and computers, 
pharmaceuticals and powder technology (Carlsson, 1997); it provides an invaluable 
resource into theoretical and empirical aspects of the technological system approach.  
 
Country specific factors in the development of the biotechnology industry have been 
extensively investigated often within a SI framework e.g. in Canada, Japan and 
Germany (Fransman and Tanaka, 1995; Arundel and Rose, 1999; Momma and Sharp, 
1999). Less work has been published on smaller or less developed economies with the 
exception of  Fontes and Novais (1998) on Portugal, Rickne (1999) on Sweden and 
various authors (Janszen and Deganaars, 1998; van Geenhuizen, 1999) on the 
Netherlands.  
1.3 Definition of Biotechnology 
The term biotechnology was coined in 1919 by Karl Ereky, a Hungarian engineer “to 
refer to the science and the methods that permit products to be produced from raw 
materials with the aid of living organisms” (OECD, 1999a). For reasons explained 
above, the economics literature has tended to focus on modern biotechnology defined 
by McKelvey as: “biological activities dependent on controlled changes to genes, and 
thereby intimately coupled to scientific fields such as molecular biology and 
biochemistry and to genetic engineering and gene therapy…” (1996, p. 81). Other 
authors have used a slightly wider definition; for example Orsenigo (1989, p. 61) 
based his analysis of patenting on the OTAF/SPRU database technical code 
                                                 
3 Other authors use the term ‘technological regime’ which would appear to be a very similar concept. 
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Bioengineering “this includes both genetic engineering and other ‘second generation’ 
biotechnology activities4…” while Eliasson and Eliasson state that: 
the biotech field is thought of as consisting of three or four sub-areas: (1) 
recombinant DNA technology, (2) use of antibodies including phage display, and 
(3) protein engineering. Sometimes also: fermentation and volume production of 
(generic) biological substances are defined as a separate biotech area. (Eliasson 
and Eliasson, 1997, p. 145). 
This study uses a narrow definition of modern biotechnology which broadly 
corresponds with the above work by Orsenigo and Eliasson. Data on activities in the 
fourth area (fermentation and volume production of biological substances) is 
presented where appropriate. The New Zealand Biotechnology Survey 1998/99 
(Statistics New Zealand, 2000) uses a classification system adapted from the 
Canadian Biotechnology Survey. This has been used to classify biotechnology 
activities into modern biotechnology (narrow definition) and biotechnology (broader 
definition through four main categories (see Table 1). 
 
Although the term ‘biotechnology sector’ is used in the title of this paper it would be 
more precise to talk about biotechnology-based sectors since as Saviotti (1998, p. 19) 
points out: 
biotechnology is not an industrial sector, but a set of techniques for the 
manipulation of living organisms which comprises several disciplines which 
provide scientific foundations for such techniques. Both the techniques and the 
scientific disciplines are used for a wide variety of applications, ranging from 
pharmaceuticals and agriculture to the environment. It is thus appropriate to talk 
about biotechnology-based sectors. 
                                                 
4 these include enzymes per se, immobilised enzymes, starch-hydrolysates, amino acids and tissue 
culture. 
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Table 1: Classification of Biotechnology Categories 
 
 Main Category Sub Categories 
DNA Based 
Technology 
Genetic engineering, Gene Probes 
Bio-informatics, Genomics 
Pharmacogenetics, Gene Therapy 
Rational Drug Design 
DNA Sequencing, Synthesis, Amplification 
Modern 
Biotechnology 
Narrow Definition 
Biochemistry or 
Immunochemistry 
based 
Vaccines, Immune Stimulants 
Drug Design and Delivery 
Combinatorial Chemistry, Diagnostic Tests 
Peptide/Protein Synthesis and Sequencing 
Cell Receptors and Cell Signalling 
Bio-Sensing, Pheromones 
Molecular Modelling, Structural Biology 
Antigens, Antibodies, Microbiology, Biomaterials 
Bio Processing5 Cell, Tissue and Embryo Culture 
Cell, Tissue and Embryo Manipulation 
Somatic Embryo genesis  
Fermentation, Bio processing, Bio transformation 
Bio leaching, Bio pulping, Bio bleaching 
Bio desulphurisation, Bio pesticide Manufacturing 
Extraction, concentration, purification, separation 
Natural Products Chemistry, Bio filtration, Bio 
indicators, Microbio inoculants, Bio Sensing 
Biotechnology 
Broad Definition 
Environmental 
Biotechnology 
Bio augmentation, Bio reactors 
Biological Gas Cleaning 
Bio remediation, Phyto remediation 
Note: The classification of main and sub categories in this table has been adapted from the New 
Zealand Biotechnology Survey 1998/99. 
                                                 
5 Excludes Classical/traditional breeding which was included in this category by Statistics New 
Zealand. Includes only those firms that use more sophisticated scientific and engineering principles for 
extraction, concentration, purification, separation and natural products chemistry. Firms using less 
sophisticated, traditional processes are classified as natural product producers and are not included in 
the biotechnology sector.  
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2. New Zealand’s National System of Innovation 
 
New Zealanders like to think of themselves as innovative people who can fix anything 
with a piece of No. 8 fencing wire6. This kind of innovation enabled many enterprises 
to develop and prosper while making do with local resources but seems to be less 
suited to competing in the global economy. Engelbrecht and Darroch (1999) used a 
range of indicators to measure innovation, knowledge absorption and diffusion and 
compared the performance of New Zealand with other OECD economies. Overall 
they concluded that “New Zealand continues to have a weak NIS7, despite the major 
changes to its research, science and technology sector since the late 1980s, and despite 
its openness to foreign direct investment”. 
 
Table 2: Selected Indicators of Innovation System Performance 
 
Indicator of: Potential to 
Produce 
Knowledge 
Inflows of 
Technology 
Absorptive Capacity Evidence of 
Diffusion 
Taking Place 
Indicator: GERD8 as 
% of GDP 
FDI Inflows 
as % of GDP 
University 
Graduates as 
% of 
Population9 
Science 
Graduates as 
% of 
University 
Graduates 
High and 
Medium Tech. 
Manufacturing 
as % of Total 
All 18 Countries 2.03 1.57 0.35 23.4 43.2 
G7 2.14 0.95 0.43 21.3 50.8 
Small 
Countries10 
1.99 2.01 0.28 24.9 37.4 
Australia 1.62 1.55 0.60 18.5 38.1 
New Zealand 0.98 4.21 0.41 14.5 24.8 
Note: All of the above data is drawn from Engelbrecht and Darroch (1999) and relates mainly to OECD 
data for 1996 from various sources.  
 
Table 2 summarises results for four out of the 14 main indicators used in their study. 
New Zealand consistently scored below Australia and below the average for G7 and 
other small, high-income OECD countries. New Zealand had the poorest record of all 
18 countries for potential to produce knowledge. The high level of FDI inflows and 
strong imports of manufactured goods mean that there should be plenty of 
opportunities for knowledge to flow into the country. However it had the lowest 
number of science graduates11 of the 18 sample countries and was ranked lowest on 
indicators of whether diffusion had actually taken place. 
                                                 
6 the gauge of wire most commonly used on farm fences. 
7 National Innovation System 
8 Government Expenditure on Research and Development 
9 i.e. the number of students graduating in 1996 as a % of the total population. 
10 Austria, Belgium, Denmark, Finland, Ireland, Netherlands, NZ, Norway, Sweden, Switzerland 
11 See Clark and Pavlovich (1999, p. 5) for anecdotal evidence on the shortage of science graduates. 
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Several of the weaknesses in New Zealand’s innovation system have been public 
knowledge for over a decade; for example Bollard et al. (1987) reported on the 1984 
Probine report which found that New Zealand’s R&D profile was affected by: the 
small scale of the economy and of most manufacturing firms; problems of isolation; 
problems of balancing applied and basic research and the limited number of scientists.  
2.1 The Science Reforms 
Problems such as these and an economy wide programme of economic reform led to a 
series of major changes to the organisation of science funding starting in 1991. The 
66-year old Department of Scientific and Industrial Research (DSIR) was dissolved 
and replaced by a system of nine Crown Research Institutes (CRI's) which operate as 
commercial companies with their own boards and two government ministers as 
shareholders. They must attain ‘profit’ targets - surpluses of ‘private’ earnings over 
expenses - set by the government, which are then retained for investment. The 
purchasing of science is carried out by the Foundation for Research Science and 
Technology (FRST) which distributes the Public Good Science Fund (PGSF). 
 
The rationale for the reorganisation has commonly been characterised as the 
application of agency theory which suggests a split between the purchaser of science 
(now FRST), and the providers (now CRI’s and others). However Upton who was the 
Minister at the time states that “the science reforms… were not a case of applying a 
theory to a sector. Rather particular outcomes were sought which the machinery of 
state sector reform ably aided and abetted” (Upton, 1995 p. 2). More recent science 
sector reforms have aimed to foster networks and increase the flow of knowledge 
between researchers, industry and business. An extensive foresight process was 
intended to focus science spending on specific science outcomes and various other 
initiatives have been announced to support innovative New Zealanders.  
 
Whatever the original rationale, the big question now is whether the reforms have 
done any good. Jacobsen (1991, p. 35) suggested that “the changes in science policy 
to date have encouraged more efficient use of research resources”. Pockley (1998) 
provides anecdotal evidence both for and against the reforms, while Simpson and 
Craig (1997, p. 75) state that “there is mounting anecdotal evidence to suggest that 
both the quality and quantity of the science [the CRI's] are producing is on the rise”. 
Alston et al (1998, p. 30) are concerned over the possible effects of reform in New 
Zealand and other developed countries. They highlight two potentially serious adverse 
effects; the removal of long-term guarantees of employment may reduce incentives 
for competent and gifted individuals to embark on research careers; and the shift in 
research resources towards agribusiness and food processing research which may 
have reduced the rate of return to public research investments. 
 
Overall, it is too early to give a definitive answer to ‘the big question’ and in any case 
the necessary data collection and analysis has not been undertaken. All of the authors 
cited above base their views on theory or anecdotal evidence rather than on any 
representative quantitative analysis. There are bound to be substantial lags in the 
transformation process so the indicators collated by Engelbrecht and Darroch would 
not be expected to show the impact of the reforms.  It has been claimed that the policy 
changes of the last decade have established a NIS in New Zealand which is unique 
amongst OECD countries (Winsley and Hammond, 1997, p. 277). The jury is still out 
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on whether this NIS will foster innovation and assist New Zealand to compete in 
world markets. 
 
2.2 The Science Base 
The strength of New Zealand’s science base is an important determinant of the 
effectiveness of the National Innovation System and should also provides a strong 
indication of the degree (if any) of New Zealand’s advantage in the area of 
biotechnology.  
 
New Zealand came first in a comparative study12 of the number of papers published 
per 100 scientists in 1993 and 1995 (Walker and Liu, 1998, p. 28). Biology and 
clinical medicine were found to account for more that half of New Zealand’s scientific 
research papers. Overall performance was evaluated in both quantitative and 
qualitative terms by using relative publication ratio13 as a proxy measure for quantity 
and relative citation rate14 as a proxy for quality.  While publication ratios in biology 
and clinical medicine were well above the world average; a possible indicator of 
advantage in these areas, citation ratios were slightly below the world average. 
 
Cole and Phelan’s (1999) investigation into the scientific productivity of nations 
found that New Zealand has a high output of scientific papers relative to the size of its 
economy. In a study of 43 countries New Zealand ranked seventh ahead of the UK, 
Canada, Australia the USA and Japan. They then used the number of highly cited 
papers15 as an indicator for the level of production of scientific knowledge. By this 
measure New Zealand’s science base is slightly below average both relative to G7 and 
to other small developed countries. They found that the strongest correlate of high-
quality papers published per capita is the number of research scientists per capita. 
This is consistent with the fact that New Zealand also has a below average number of 
scientists. 
 
Further data on the relative quantity and quality of New Zealand science publishing is 
available from the ISI database for 1994-98 (Institute for Scientific Information, 
2000). New Zealand authors wrote 0.56% of all 1994-98 science and social science 
papers on the database. New Zealand papers were heavily concentrated in areas such 
as agricultural, plant and animal sciences, geosciences, ecology and environmental 
sciences. The citation impact16 of New Zealand papers in these areas was within 10% 
of the world average. Papers in pharmacology were frequently cited with a relative 
impact of +72%, while citations in microbiology and molecular biology, biology and 
biochemistry were all below average. Data from the SCI17 database for 1980 –1995 
paints a similar picture. 
 
                                                 
12 compared to a reference group of countries comprising Australia, Denmark, Finland, Ireland, 
Norway and Sweden. 
13 Relative Publication Ratio is the ratio between a country’s papers in a field as a percentage of total 
country papers, and the percentage of world papers in that field.  
14 Relative Citation Rate is the average citation for New Zealand papers in a field relative to the 
average citation rate for all papers in the Science Citation Index. 
15 Based on the number of papers published in 1987 which received 40 or more citations by the Science 
Citation Index between 1987 and 1991. 
16 this is the same as Relative Citation Rate (see above) 
17 Unpublished data provided by the Ministry of Research, Science and Technology 
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Berridge (1999) analysed New Zealand science publications using the science citation 
index database18. Total New Zealand publications as a percentage of total world 
publications fluctuated between 1990 and 1995, and increased from 1996-99, mostly 
attributable to more publications by universities. He also found that: 
relative to world publications, non-university publications declined by 3.5% per 
year over the 1990-96 period and appear to have stabilised since. Interestingly 
publications with Ag in their institutional title increased steadily 1990-99, both as 
total publications and as a percentage of total world  publications. 
He concluded that “science restructuring has had some deleterious effects on science 
performance in non-university science institutions as measured by international 
publications” and that publications in the agricultural and medical fields have run 
counter to these trends and increased. 
 
Overall, New Zealand’s science base is relatively small (compared to G7 and small 
OECD countries) and is heavily skewed towards certain areas (e.g. biology, clinical 
medicine and agriculture). New Zealand scientists have a high productivity (measured 
by papers per scientist) but New Zealand science is not highly cited internationally 
except in a handful of specialist areas e.g. pharmacology. 
 
3. Biotechnology in New Zealand 
 
Despite the small size of its economy and of its science base New Zealand has had a 
significant role in the biotechnology revolution. New Zealand contributed to the birth 
of modern biotechnology through the first description of the structure of DNA by a 
New Zealand biophysicist, Dr Maurice Wilkins who was later jointly awarded the 
Nobel Prize with Crick and Watson (New Zealand Trade Development Board, 2000, 
p. 2) 
 
Much of New Zealand’s work builds on national strengths in agricultural and primary 
industry production and research. But there are also a number of new enterprises at 
the forefront of research in health and in intellectual property. Recent examples cited 
by BIOTENZ (1998) include: 
 
• Breeding of transgenic crops with virus and insect resistance. 
• Clonal afforestation through the development of micro propagation techniques              
to select superior tree variants for large scale forestry. 
• Genetic manipulation of flower colour. 
• The world's first enteric bacteria-based bio insecticide, for the control of grass              
grubs.  
• Test kits using monoclonal antibodies for residues in plant and animal tissue. 
• A project to map the sheep genome - The world's first sheep genetically 
engineered for increased wool production.  
• The world's first recombinant livestock vaccine, to combat sheep measles. 
 
Most modern biotechnology activities in NZ are concentrated in universities and 
CRI’s and a small number of private sector companies e.g. Genesis (Probe, 
                                                 
18 the ISI web of Science, Science Citation Index Database 
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ViaLactia). The government has been estimated to spend around NZ$100m a year19 
on biotechnology-related research ranging from genomics to processing of natural 
products” (Rolleston, 1999, p. 46). Genesis has invested NZ$41 million in research 
since its inception in 1994 while CRI’s and companies such as Auckland UniServices 
have also been successful in generating research revenue from outside the government 
sector. Nonetheless it must be recognised that New Zealand’s total expenditure on 
biotechnology research is very small by global standards. Total public and private 
R&D expenditure in 1998 would not have exceeded NZ$150 million20 – around 1% of 
the R&D expenditure by the 330 public biotech companies tracked by Ernst & Young 
(1999b) in their annual survey of the international biotech industry. 
 
Few innovations or processes in modern biotechnology have reached the stage of 
being commercialised for example the CEO of a large research institute indicated that 
“most of our work is in the early discovery or experimental stage where we are 
genetically engineering animals to get proof of function21”. Genesis Research and 
Development is perhaps closest to achieving income from a new biotechnology 
product – it received FDA clearance to start phase II Psoriasis clinical trials in January 
2000; one of over 300 biotech products now in phase II or phase III trials…(Ernst & 
Young, 1999b, p. 35). 
 
A study was conducted by Tradenz in 1994  to investigate the foreign exchange 
earning potential of the pharmaceutical and biotechnology industry. Taking a 
relatively broad definition of biotechnology it was concluded that total turnover was 
around NZ$330 million with foreign exchange receipts of around NZ$137 million 
(around 0.7% of total merchandise exports). Industry estimates of growth rates for 
different categories of firm ranged from 16 to 25% per annum. These figures exclude 
traditional areas such as dairy and other food production e.g. New Zealand Dairy 
Exports of NZ$4.6 billion in 1998/9. If biotechnology in traditional food applications 
(Cheese, yoghurt, beer) and natural health products including deer velvet are added 
BIOTENZ estimate that the industry could have a turnover of NZ$7-11 billion by 
201022. 
 
Little hard data on the size and activities of modern biotechnology firms in New 
Zealand is available; this will be rectified by the present study and a survey of 
organisations involved in biotechnology which will be conducted by Statistics New 
Zealand in the current year.  However a preliminary analysis of the New Zealand 
modern biotechnology sector has been carried out using a database of firms and 
research organisations built up from website information on the members of the New 
Zealand Biotechnology Association and BIOTENZ and from a search of New Zealand 
newspapers, magazines, journals and the NZBA newsletter. All organisations 
                                                 
19 Total spending on ‘the Science Envelope’ for 1999/2000 is estimated at NZ$586 million (Ministry 
of Research Science and Technology, 1999, p. 7). New Zealand’s 1999 GDP was NZ$98.9 
billion. 
20 Ernst & Young (1999a) estimated Australian total R&D expenditure on biotechnology in 1998/99 
to be A$491 million (NZ$614 million) 52% being government funded. On a population basis Australia 
would be expected to spend five times as much as NZ. However the estimate for New Zealand is for a 
broader definition of biotechnology and so is not comparable.  
21 Interview A, 11 April 2000 
22 Based on 2.5% p.a. annual growth GDP would be around NZ$130 billion – so this would be around 
7% of GDP. 
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described by Kennedy and Davies in their description of “The Impact of 
Biotechnology on New Zealand Industry 1984 - 1994” (1994) were also categorised 
and included in the database, with information being updated where possible. An 
outline of the New Zealand’s biotechnology sector based on this analysis is presented 
as Table 3.  
 
It may be seen that the modern biotechnology sector consists of approximately 40 
organisations (20 private companies, 2 trade organisations, 11 research organisations 
and 7 universities) employing of the order of 1250 people. A further 40 firms are 
involved in various kinds of bio processing activity and employ over 500 people in 
‘biotech based activities’. Table 3 also includes 30 firms involved in the production of 
natural products or nutraceuticals that are members of NZBA or BIOTENZ.  
 
Table 3: An Outline of the New Zealand Biotechnology Sector 
 
 Private 
Sector Firms 
Producer 
Boards 
Research 
Organisations 
Universities 
# Organisations 10 2 (+?) 11 7 
# Employees 300 ? 450 150 
DNA Based 
e.g. genetic 
engineering, 
genomics, bio-
informatics 
Examples Genesis, PPL 
Therapeutics, 
Fletcher 
Challenge 
New Zealand 
Dairy Board – 
ViaLactia, Wool 
Board 
AgResearch, 
HortResearch, 
Mallaghan 
Institute 
Auckland, 
Otago, 
Massey, 
Waikato, 
Lincoln 
# Organisations 10 
# Employees 350 
Biochemistry/ 
Immunochemisry 
e.g. vaccines, protein 
synthesis, antigens, 
antibodies 
Examples Immuno-
Chemical 
Products Ltd 
See above (most of these are also involved in 
biochemistry/immuno chemistry based 
activities). 
# Organisations 40 
# Employees 550 
Bio processing 
e.g. fermentation, cell 
& tissue culture, bio 
pesticides Examples Tatua, NZ Pharmaceuticals 
 
# Organisations 2 (+?) 
# Employees 25 
Environmental 
Biotechnology 
e.g. bio 
augmentation, bio-
remediation 
Examples Waste Solutions 
Ltd 
 
# Organisations 30++ 
  
Natural Products 
and 
Nutraceuticals Examples Herb Farm, 
Zeal Extracts 
Ltd 
Note: data in this category is for NZBA and 
BIOTENZ members only. 
Note: Data in this table should be regarded as preliminary. Estimates for number of organisations in 
each category have been rounded. Estimates for number of employees ‘in biotech’ are from NZBA data 
base and other sources. Organisations above the bold line fall under the modern biotechnology sector. 
3.1 Trade and other Organisations Concerned with Biotechnology 
Since biotechnology cuts across a range of industries there are several different trade 
organisations with a strong interest in the subject ranging from agricultural (dairy, 
meat, deer and wool) and horticultural (pip fruit, citrus growers, kiwi fruit) through to 
medical e.g. Health Research Council. The New Zealand Biotechnology Association 
(NZBA) provides a broad forum to represent the interests of “those concerned with 
biotechnology in New Zealand23”. It uses an amended version of the OECD 
                                                 
23 Objectives of the NZBA at http://www.biotech.org.nz/objectives.htm 
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definition24 of traditional biotechnology “the application of scientific and engineering 
principles to the processing of material by biological agents and the processing of 
biological materials to improve the quality of life” and so includes a range of 
companies which produce or sell natural products, nutraceuticals and dietary 
supplements. Their web site lists 90 members in their on-line directory; including 
manufacturers, processors, distributors, consultants and research organisations. They 
publish a quarterly newsletter and hold an annual conference. 
 
BIOTENZ is a group of leading New Zealand providers of biotechnology and                    
pharmaceutical products and services. BIOTENZ is supported by Tradenz, the New                    
Zealand Government's export promotion arm25. The BIOTENZ website lists 38 
members, many of whom are also members of NZBA. A number of organisations 
have also been active in setting up the Life Sciences Network which is an attempt to 
bring together companies involved in biotechnology26. The Independent 
Biotechnology Advisory Council (IBAC) was established in 1999 with the objective 
of stimulating dialogue and enhancing public understanding about biotechnology. It 
will also provide independent advice to government on environmental, economic, 
ethical, social and health aspects of biotechnology27. The council’s work has, at least 
for the next year been somewhat overtaken by the appointment in April of a Royal 
Commission on Genetic Modification which will: 
inquire into and report on the strategic options available to enable New Zealand to 
address genetic information now and in the future. The Royal Commission may 
also recommend any changes in the current legislative, regulatory, policy or 
institutional arrangements for addressing genetic modification technologies and 
products in New Zealand (Royal Society of New Zealand, 2000b). 
3.2 Private Sector Modern Biotechnology Firms 
New Zealand has very few ‘classic’ biotech firms based on the development and 
commercialisation of intellectual property. By far the largest is Genesis Research and 
Development, which focuses on the generation of EST28 databases from microbes 
plants and animals and searching for genes of economic importance. Genesis has over 
90 employees and a rapidly expanding intellectual property portfolio29. Genesis has 
partnerships with Fletcher Challenge and Carter Holt Harvey30; large forestry 
companies which have invested heavily in biotechnology in New Zealand. Fletchers 
has been involved in commercial production of cloned pine trees through somatic 
embryo-genesis for several years. Carters followed the more difficult organo-genesis 
route and is now ready to start trials of genetically modified trees. Both companies 
took leading roles in promoting biotechnology research in association with the 
Forestry Research Institute31. As a result this is now an area where New Zealand 
based firms and scientists are at the forefront of technology; Arborgen the world’s 
leading forestry biotechnology company is a joint venture between two huge US 
                                                 
24 See Bull (1982) 
25 BIOTENZ web page at http://www.biotenz.org.nz/ 
26 Interview A, 11 April 2000 
27 IBAC web page at http://www.ibac.org.nz/terms.htm 
28 Expressed Sequence Tag – single pass sequence files of an organisms expressed genome. 
29 11 patents issued, 3 granted, 80 applications (interview, 5 April 2000) 
30 through it’s parent International Paper 
31 interview D, 1 May 2000 
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companies (International Paper and Westvaco Corporation) and three New Zealand 
companies (Fletcher Challenge Forests, Genesis and Carter Holt Harvey).  
 
Other firms are involved in research and trials towards use of genetically modified 
organisms e.g. PPL Therapeutics which has a flock of genetically modified sheep 
which will be used to produce a human protein for treatment of cystic fibrosis and 
New Zealand King Salmon which is researching growth-enhanced salmon using 
genetic manipulation techniques (NZBA, 1999). Another company is involved in 
genetic improvement in plants and “is best known for its success in developing novel 
coloured varieties of cut flowers”(NZPA, 2000b). Multinational  agricultural 
biotechnology companies e.g. Pioneer and Monsanto are represented in New Zealand 
although no genetically modified crops have progressed beyond field trials. 
 
Production of vaccines, antigens, antibodies and associated technologies is an area 
where New Zealand is relatively strong e.g. Immuno-Chemical Products Ltd which 
manufactures and markets embryo transfer chemicals, hygiene test systems and 
biochemicals. There are also a number of pharmaceutical firms with local research 
and production facilities which are involved in the biotechnology sector to some 
degree; for example Bomac a producer of animal health products has provided 
funding to enable a multi-million dollar expansion of Massey University’s Institute of 
Veterinary & Biomedical Science (Leech, 1999). 
 
A number of small biotechnology companies are either university spin-offs or have 
other strong university links. Auckland UniServices has probably the strongest record 
in establishing such companies: 
Based on the work of a team led by Professor Peter Gluckman at the University of 
Auckland Medical School, Auckland UniServices has established a spin off 
company, NeuronZ Ltd, that is pioneering a revolutionary therapy for rescuing 
brain cells damaged by injury and stroke. Another UniServices company, 
Physiome, a joint project with Oxford and Johns Hopkins Universities based in 
New Jersey, is developing world-first technology for computer modelling of 
human organs. (New Zealand Trade Development Board, 2000, p. 3) 
Other companies have strong links with, or are owned by other New Zealand 
universities particularly Lincoln, Massey, Otago and Waikato. 
3.3 Private Sector Bio Processing Firms 
New Zealand also has a large group of bio processing firms that might be included in 
a broader definition of the biotechnology sector. These range from sophisticated 
operations e.g. manufacture of purified protein and bioactive peptide fractions from 
milk to simple extraction of raw materials from natural products e.g. essential oils. 
The more sophisticated firms are mainly involved in extraction of high value products 
either from milk or from animal by-products. Some firms were founded to take 
advantage of a ready supply of animal by-products but have grown to the extent 
where they import most of their raw materials (and find that imported products are 
cheaper than those available on the domestic market). 
 
None of the traditional biotech firms interviewed to date had any plans to move into 
modern biotechnology – indeed some are already competing against products 
produced using GM organisms and use their ‘natural’ production methods to gain 
marketing advantage.  
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3.4 Producer Boards and Trade Organisations 
There have been some major initiatives recently to investigate how New Zealand’s 
primary industries should react to, or participate in the biotechnology revolution. Both 
the wool and dairy boards have recently completed reviews with the assistance of 
outside consultants. The sheep industry is reported to have acquired “a very good base 
for driving forward in biotechnology [that was] … totally driven by scientists … 
irrespective of what the industry thought they needed32”. 
 
Early in 1999 the New Zealand Dairy Board (NZDB) announced that it would boost 
its research spending by up to NZ$150 million over the next five years to investigate 
the potential of biotechnology (NZPA, 2000a). This followed a comprehensive 
investigation by an industry wide team including AgResearch (New Zealand’s largest 
CRI) and outside consultants which concluded “that an opportunity existed for New 
Zealand to lead the world in dairy biotechnology and that the potential benefits could 
be in the region of one billion dollars” (NZDB, 1999). The investment is to be 
concentrated into three main areas: forage biotechnology, marker assisted selection 
and transgenics.  
 
Research into ryegrass and white clover will use biotechnology to increase the 
productivity of New Zealand’s pasture based dairy production system. The ability to 
accurately assess genotype will accelerate the rate of genetic gain in the national dairy 
herd. Research into cloning and transgenics “will position the New Zealand dairy 
industry to take advantage of these technologies if it so wishes” (Marshall, 2000, p. 
171). The industry’s investment in biotechnology and the associated intellectual 
property is to be managed by a wholly owned NZDB subsidiary called ViaLactia. It is 
reported that ViaLactia will be a relatively small company which will outsource R&D 
from leading research organisations both in New Zealand and overseas. ViaLactia 
recently announced its first major outside research contract - with Celera Genomics: 
ViaLactia Biosciences New Zealand Ltd, a subsidiary of the Dairy Board, has 
signed an agreement with Celera Genomics of Rockville in the United States 
which will enable more rapid improvement of the national dairy herd, particularly 
through better sire selection…This pilot project will sequence around 10 percent 
of bovine genes and will be a forerunner of a much larger project involving a 
greater number of target genes. An early output from the project will be the 
identification of ‘gene markers’ for livestock selection. The availability of these 
markers will enable the use of DNA profiling to identify milk production and 
other traits in individual animals and thus facilitate more precise natural selection 
for breeding (Royal Society of New Zealand, 2000a). 
3.5 Research Organisations 
Several of New Zealand’s Crown Research Institutes (CRI’s) are taking a leading role 
in biotechnology research. “The largest CRI, AgResearch has five research campuses, 
over 1100 staff, of whom nearly 200 have PhDs and an annual research budget of 
NZ$90 million (New Zealand Trade Development Board, 2000, p. 4). 
 
AgResearch operates a molecular biology unit in conjunction with the University of 
Otago which is building genetic maps for sheep and identifying DNA markers for 
disease resistance, reproduction, wool quality, meat quality and other desired 
characteristics. The unit also “owns and operates the international databases for sheep 
                                                 
32 Interview F, 8 April 2000 
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and deer genes. The sheep map contains 100,000 genes that may find expression in 
new protein products and services” (Mazoyer, 1999, p. 6). 
 
AgResearch is also working on development of transgenic livestock (L'Huillier, 2000, 
p. 186) and has applied to the New Zealand Environmental Risk Management 
Authority (ERMA) to undertake genetic modification studies for potential 
applications in therapeutics and functional foods. “This work has two ultimate 
applications… firstly for the possible development of a new treatment for multiple 
sclerosis; and secondly, to modify milk composition to make it richer in casein or 
reduce its content of beta-lactoglobulin” (AgResearch, 1999, p. 9). 
 
The CRI's also have a number of spin-off companies which handle their 
biotechnology products e.g. AgVax which manufactures toxoplasma33 and other 
vaccines; and Genomnz which uses genetic identification technology to identify 
parentage and characteristics of animals. 
3.6 Universities 
New Zealand universities have been active in various aspects of modern 
biotechnology. Massey University began the first undergraduate degree course in 
1967 and has a strong record in several areas including structural biology. In 1978 
Baker succeeded in solving the 3D structure of actinidin, an enzyme from kiwi fruit 
“even today with more than 1000 protein structures solved this remains one of the 
‘best’ structures in the protein database and it enabled a great deal of new information 
to be uncovered about how protein structures are built and stabilised (Baker, 1998, p. 
12)”. Researchers at Massey University went on to solve the structure of lactoferrin. 
“This established international credibility and enabled the build up of the critical mass 
of researchers that is essential to build up a vigorous research programme” (Baker, 
1998, p. 13). Professor Baker now heads the Laboratory for Structural Biology at the 
University of Auckland that comprises some 25 researchers, including 3 academic 
staff and 12 Postdoctoral fellows (Farrell, 1999, p. 6). 
 
The University of Auckland Medical School is another centre of research excellence 
which has led to the creation of several spin-off companies34. Jim Watson was head of 
the Department of Molecular Medicine before he used his understanding of signalling 
molecules35 to found Genesis Research and Development. Researchers at the 
University of Waikato have strong links with the forestry industry and are working on 
a joint project to develop and commercialise bio control products for use against 
sapstain36. The university also owns Pacific Enzymes which works on the “isolation 
of novel thermophilic organisms which express industrially useful enzymes and the 
cloning of their respective genes”37. 
 
The University of Otago runs a Molecular Biology Unit in conjunction with 
AgResearch which works on molecular tools for genome analysis and is an 
                                                 
33 toxoplasma infections are a key cause of abortion in sheep (New Zealand Trade Development Board, 
2000, p. 12) 
34 See Auckland UniServices in the section above on Private Modern Biotechnology Companies 
35 Inteview E, 5 April 2000 
36 Sapstain is caused by a specific fungi which invades radiata pine causing revenue losses estimated at 
NZ$100 million p.a. 
37 NZBA web pages: http://www.biotech.org.nz/dir/pacificenzymes.htm 
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international leader in the application of sheep and deer gene maps for agricultural 
and biomedical research38. A Lincoln University spin-off company has developed a 
biosensor that uses whole microorganisms to “slash the time needed for 
environmental testing of pollutants in waste water from five days to an hour” (Birss, 
2000). 
 
The examples outlined above illustrate the existence of several pockets of excellence 
in the university sector. While a number of these have been associated with the 
creation of spin-off companies, there is no sign that New Zealand is likely to 
experience anything like the surge of biotech start-up activity that was experienced in 
the United States. 
3.7 Data from Patenting 
The use of data from patenting as an indicator of innovative activity has been well 
established for many years39. There is also a rapidly increasing literature in the 
biotechnology area based on analysis of patents (Joly and Looze, 1996; Malo and 
Geuna, 1999; Foltz, Barham and Kim, 2000; McMillan, Narin and Deeds, 2000). 
 
A preliminary analysis of New Zealand patenting activity in biotechnology was 
carried out using international applications published in the Patent Cooperation Treaty 
(PCT) Electronic Gazette40. The PCT provides for the filing of an international 
application to have the same effect as a national application in each of the contracted 
states designated in the application (OECD, 1994, p. 19); it thus provides a useful 
measure of international patenting activity. Use of applications data provides a more 
immediate picture, since it can take up to five years from the first application for a 
patent to be granted41. 
 
Methodology based on Engelbrecht and Darroch (1999) was used to compare New 
Zealand’s rate of patenting with G7 and a reference group of high-income OECD 
countries (see Table 4). For the purposes of this analysis modern biotechnology was 
taken to be synonymous with the International Patent Class C12N, while a ‘Broad 
Definition’ of biotechnology included a number of other classes detailed below42.  
 
New Zealand’s rate of modern biotech patent applications at 8 per million of 
population is below the average for the G7 (13.6) and for a reference group of small 
developed OECD economies (15.4); these results are essentially unchanged when the 
broader definition of biotechnology is used. Patent application rates range from a high 
of 44 for Denmark to a low of 1.4 for Italy. Overall New Zealand ranks twelfth out of 
18 with a patenting rate slightly above that found in France, Germany and Japan. 
However New Zealand’s performance is disappointing compared to other small 
countries with strong primary industries that it might hope to emulate e.g. Denmark 
(44.1), Netherlands (16.6), Australia (12.1).  
 
                                                 
38 University of Otago web pages: http://www.otago.ac.nz/research/centres/units/res_unit_molecular_biol.html 
39 See Griliches (1990) for an excellent survey. 
40 Web page: http://pctgazette.wipo.int/ 
41 Lead times for patent application procedures are summarised in OECD (1994, p. 27). 
42 Includes A01G, A01H, A01N, C12M, C12N, C12P, C12Q – defined as ‘General Biotechnology’ by 
Joly and de Looze (1996). 
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Table 4: New Zealand and OECD Patenting Rates in Biotechnology 
 
 PCT Patent Applications 
(1 Jan 1997 – 15 May, 2000) 
per million population 
 C12N 
Modern 
Biotechnology 
Broad 
Definition 
All 18 
Countries 
13.8 22.5 
G7 13.6 22.2 
Small 
Countries43 
15.4 25.7 
Australia 12.1 19.1 
New Zealand 8.0 15.7 
 
 
Table 5 breaks down New Zealand patent applications by organisational type. While 
the results are broadly consistent with the relative size of the different groups (see 
Table 3), they also indicate a higher rate of patenting by universities and private 
companies compared to Crown Research Institutes. Genesis and it’s partner Fletchers 
dominate private sector patenting; they were responsible for 37% of all PCT 
applications under patent class C12N. 
 
Table 5: Breakdown of New Zealand PCT Patent Applications 1997-2000 
 
International Patent Class 
 
C12N Broad 
Definition 
No of Patent Applications 30 59 
No of Different Applicants 24 46 
Total NZ Applicants 35 69 
Breakdown of NZ Applicants: 
Private companies and individuals 63% 62% 
of which Genesis, Fletchers & subsidiaries 37% 20% 
Crown Research Institutes 17% 20% 
Universities (including associated companies) 17% 12% 
Producer Boards 3% 6% 
Total NZ Applicants 100% 100% 
                                                 
43 Austria, Belgium, Denmark, Finland, Ireland, Netherlands, NZ, Norway, Sweden, Switzerland 
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4. Factors Affecting Innovation 
4.1 The Innovation System for Biotechnology 
The OECD’s Oslo Manual (1997, p. 31) lays out a useful framework that allows us to 
relate science investment to all the other factors that may affect innovation.  It 
describe four categories of factors relating to innovation: 
 
C the framework conditions of national institutional and structural factors 
e.g. economic, financial and educational setting and the rules and range of opportunities for 
innovation 
C the science and engineering base 
the accumulated knowledge and the science and technology institutions which underpin 
innovation 
C transfer factors 
which strongly influence linkages and flows of information etc which are essential to 
innovation 
C the innovation dynamo 
dynamic factors shaping innovation at the level of the firm  
 
In other words, science investment is only one of a large number of factors that affect 
the rate of innovation. Even the best managed science investment may have poor 
outcomes if other aspects of the innovation policy terrain are in poor shape e.g. if 
there is a shortage of appropriately trained staff; if the economic climate discourages 
innovation; or if the network of institutions firms and organisations does not have a 
system of linkages which encourages the effective dissemination of results. 
 
The heading of this section begs the question as to whether New Zealand does have a 
network of institutions firms and organisations, an innovation system, which 
encourages the effective dissemination of results. The system, if it exists, is dominated 
by crown research institutes and universities which rely on the government for the 
majority of their funding. Research and teaching in biotechnology is carried out in 
seven of New Zealand’s eight universities. Biotechnology research is also carried out 
at eight of the country’s nine Crown Research Institutes44. Indeed this spread of 
activity has been argued to be a serious waste of resources by some who believe that it 
would be more efficient to concentrate biotech research into a smaller number of sites. 
 
Data from interviews with biotech industry representatives carried out as part of this 
study provide little evidence for the existence of a well functioning innovation system 
for biotechnology. Private firms did not place high importance on strong linkages with 
CRI’s and universities.  Universities and CRI’s do not generally have particularly 
strong linkages; indeed the relationship is often more one of competition for scarce 
research funding. Nor is their much movement of staff between CRI’s, universities 
and the private sector. Turnover at the CRI HortResearch was reported to be 3-5% per 
annum “there were limited cross-CRI transfers and just a few people moving on to 
universities or polytechnics” (Clark, Pavlovich et al., 1999, p. 6). 
 
                                                 
44 this under represents the geographic spread of biotech research since most CRI's are spread over 
several different campuses. 
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Some private firms placed little emphasis on linkages in development of 
biotechnology innovation; others found few organisations worth linking with (perhaps 
because the modern biotechnology sector in New Zealand is so small) – and so 
concentrated on developing strategic alliances and joint ventures with overseas 
partners. Others felt that CRI’s and universities have little to offer them: 
they operate on a completely different time horizon … the difference between 
commercial reality and university and government research is so wide that most 
people cannot understand that what they are doing never actually achieves a 
desired outcome (interview C, 30 March 2000).   
This view is supported by another biotech CEO quoted in Mazoyer (1999): “NZ does 
not have a broad range of public research agencies that are well inter-linked. There 
may not be much cross-over into industry – in fact the public research system seems 
to operate in a sector of its own”. Opinion is divided as to whether it is the public 
research agencies which don’t meet the needs of the private sector45 or the private 
sector which has a limited ability to apply the results of publicly funded R&D or to 
evaluate opportunities (Winsley, Couchman and Gilbertson, 1998, p. 61). It is not 
surprising then, that Mazoyer goes on to conclude that “commercialisation is 
sometimes hindered by a lack of interaction between the science sector and 
manufacturers … [and that] more effective learning interactions and networking 
between scientists, public and private investors and users need to be encouraged” 
(1999, pp. 6-7). 
 
Modern biotechnology activity in New Zealand may perhaps be better described 
through the idea of ‘islands of excellence46’. Leading edge work is carried out in a 
number of areas; but these islands of excellence tend to collaborate strongly with a 
small number of other organisations rather than being strongly connected to any wider 
innovation system. A good example is provided by the forestry industry where a small 
number of leading companies collaborated with the Forest Research Institute to 
promote research into forest biotechnology. Carters were able to develop the ability to 
genetically transform pine trees using a company scientist, a recent graduate with an 
MSc in biotechnology and email contact with a colleague in Canada47. The innovation 
system for forestry biotechnology in New Zealand is now concentrated on the biotech 
company Arborgen and its shareholders.  
 
Similarly Genesis was founded using intellectual property from the University of 
Auckland and has strong partnerships with two CRI's, the New Zealand Dairy Board 
and six overseas companies. However Genesis can probably be best characterised as 
being part of the international innovation system for biotechnology rather than having 
particularly strong links with many New Zealand based institutions. 
4.2 Framework Conditions for Innovation 
Many of those interviewed for this study had serious concerns about New Zealand’s 
framework conditions for innovation. They focussed particularly on “the lack of a 
pro-business environment, national attitudes to entrepreneurs and risk takers and the 
regulatory framework which has made New Zealand an expensive country in which to 
do business”. One interviewee cited the recent increase in the top rate of income tax 
                                                 
45 see also Frater, Stuart, Rose and Andrews (1995, p. 179) 
46 also the title of a 1993 report by the New Zealand Institute of Economic Research 
47 interview D, 1 May 2000 
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as an example of negative attitudes to business that has harmed their ability to recruit 
scientists internationally. He also expressed the opinion that “we don’t like people 
being enterprising, we don’t admire people being rich [and]… if we don’t have an 
admiration for people taking risks and being successful then we won’t have 
innovation in biotechnology48. 
 
Work on genetically modified and new organisms in New Zealand is controlled by the 
Hazardous Substances and New Organisms (HSNO) Act 1996 which aims to “protect 
the environment, and the health and safety of people and communities, by preventing 
or managing the adverse effects of hazardous substances and new organisms” 
(Environmental Risk Management Authority, 1999). Serious concerns have been 
expressed both about the degree of control and the associated delays: “it can take 18 
months to get approval from ERMA to do a piece of research … by the time you get 
approval to do it, it is a whole new world, literally”49. The University of Otago 
recently fell foul of ERMA regulations on “a very low risk project that in any other 
country would not require the approval of a regulatory authority” (Cassie, 2000).  
 
Firms involved in extracting high value products from animals also commented that 
various regulations administered by the Ministry of Agriculture and Forestry (MAF) 
increased their costs and put them at a competitive disadvantage when exporting. A 
new Animal Products Act which came into effect in 1999 regulates the            
production and processing of animal material and products in order “to protect human 
and animal health and facilitate overseas market access”50. Hopefully this Act will 
reduce these problems and prove to be less prescriptive. 
 
On the positive side; research costs are estimated to be 40% below international levels 
(New Zealand Trade Development Board, 2000, p. 4). This and New Zealand’s 
rigorous border controls and relatively disease free status have been pushed heavily 
by BIOTENZ and the New Zealand Trade Development Board in an attempt to 
increase overseas funding of biotechnology activities in New Zealand.  
 
Unfortunately these low research costs are a double-edged sword when it comes to 
attracting overseas talent and retaining top New Zealand scientists as illustrated by the 
following quotes from Petersen and a CRI manager: 
We were recruiting a plant breeder. We had a very good candidate from the US 
who we brought out here. We paid for him to come out. We said we don’t want 
you to come just for an interview, come for a week. You need to find out about us 
and we need to find out about you. He was our preferred candidate. We offered 
him between $5,000 - $10,000 more per annum starting salary. So we really 
wanted this person. But he converted his dollars back and said “No” (Clark, 
Pavlovich et al., 1999, p. 5).  
Petersen (1998) was initially the only scientist working on DNA chemistry in the 
Southern Hemisphere. DSIR encourage his research even though it was clear that any 
possible applications were years off …  Petersen makes some excellent points on how 
internationally competitive research should be supported in New Zealand: 
If we want our research to be internationally competitive, then our graduates have 
to trained to international standards and be given internationally-equivalent 
                                                 
48 interview E, 5 April, 2000 
49 interview A, 11 April 2000 
50 MAF web site: http://www.maf.govt.nz/animalproducts/ 
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research opportunities. Yet this makes them susceptible to offers from other 
countries and, and if we want them to stay in New Zealand or return to New 
Zealand after their post-doctoral training, we are going to have to do that extra bit 
to make them want to make their long-tern careers in their own country (Petersen, 
1998, p. 7). 
4.3 Government Policy 
Over the six years from 1984 to 1991 New Zealand engaged in “one of the most 
radical market liberalisation programmes initiated anywhere in the world” (Massey, 
1995, p. xii), “transforming New Zealand from the most to the least regulated 
economy in the OECD” (Hazeldine, 1998, p. 1).  
Interest rate controls were removed, agricultural subsidies were phased out, New 
Zealand moved to a floating exchange rate regime, monetary policy was given a 
single statutory objective of maintaining price stability, detailed industrial and 
occupational regulations were replaced with a generic commitment to competitive 
markets, import quotas and tariffs were eliminated or reduced, public sector 
management was reformed, trading departments were converted into State-owned 
enterprises with a clear commercial focus, and a programme of selling State assets 
was commenced (Dalziel, 1999, p. 1). 
These non-interventionist, free market policies continued to dominate the New 
Zealand political scene until the election of a new Labour government in 1999. There 
have been neither large-scale policy interventions designed to increase R&D spending 
nor major funding initiatives to promote biotechnology. Indeed government and 
industry only seem to have started taking a close interest in biotechnology in the last 
three to four years51.  
 
There are now signs of a more interventionist approach to science policy. As part of 
the most recent round of policy adjustments New Zealand’s Foundation for Research, 
Science and Technology (FRST) has developed a series of Strategic Portfolio Outlines 
(SPO’s), which will guide its investments. Investment in biotechnology falls under the 
Advanced Biological Enterprises SPO which aims to: 
generate wealth for New Zealand by assisting the migration of the country’s 
economy into new and emerging markets. To do so, this SPO will seek to develop 
a coordinated and focused approach to establishing a vibrant biotechnology-based 
sector (Foundation For Research Science and Technology, 2000, p. 1) 
The document goes on to describe “principles and behaviours to be encouraged” 
which include52: 
• the need for a targeted, rapid and flexible investment system by Government; 
• the development of an entrepreneurial spirit; 
• partnerships and linkages between stakeholders; 
• increase global linkages to exploit New Zealand’s competitive advantage; and 
• enhanced integration and leadership among sector groups and along value 
chains. 
 
New Zealand’s approach has contrasted strongly with some of its regional trading 
partners. In Australia, the federal government established two new agencies “to ensure 
Australia realises the potential gains being offered by biotechnology”53. The 
                                                 
51 Interview F, 8 April, 2000 
52 See FRST web page: http://www.frst.govt.nz/public/foresight/spo/ABE.htm 
53 See Biotechnology Australia web page: http://www.isr.gov.au/ba 
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Singapore Government has a strategy ‘to position Singapore as the strategic hub for 
the pharmaceutical, biotechnology and health care industry in Asia’ while Taiwan 
aims to develop into ‘an Asia-Pacific R&D Center’ and ‘an Asia-Pacific 
Manufacturing Center for high-tech products’. Taiwan currently spends NZ$200 
million per year on biotech and is increasing its technology budget by 10-15% per 
year (Rolleston, 1999, p. 43).  
 
There is a significant level of dissatisfaction with government policy towards 
research, science and technology in New Zealand. Comments such as “I don’t think 
science management in New Zealand has been a great success” and “put money into 
the private sector not FRST”54 are frequently heard. A more specific criticism is that 
“the science reforms produced an over-emphasis on incremental innovation or 
technology and undermined the science base, leaving less time for research from 
which big new ideas could emerge” (quoted inMazoyer, 1999, p. 9). 
 
A “focus on small projects focussed on individuals has taken away the ability of 
CRI’s to build future science capabilities”55. This is supported by Petersen (1998, p. 
10) who suggests “there must be some mechanism that allows scientist to be kept on 
the payroll while alternative funding routes are worked out”. There is a serious brain 
drain of students completing PhD’s “because they are not prepared to spend the rest of 
their lives living from hand to mouth on short-term contracts”. 
 
The impact of funding constraints is commented on by Baker (1998, p. 15) “ I 
consider it a tragedy that New Zealand has no agency that can fund major equipment. 
It severely limits our ability to take advantage of the new opportunities in the current 
biological revolution”.  
 
On a more positive note some interviewees found that government programmes to 
encourage technology transfer were useful. They attributed low uptake of these 
programmes to company culture and short termism. Others said accountability 
requirements in using TBG, PGSF and GRIF are excessive (Mazoyer, 1999, p. 10). 
4.4 R&D Funding 
It has been well known for some years that New Zealand’s expenditure on R&D is 
low relative to other OECD members. In 1996 New Zealand’s gross expenditure on 
R&D (GERD) was 0.98% compared to 2% or over for G7 and a group of small 
OECD countries (Engelbrecht and Darroch, 1999). Spending by New Zealand 
industry, as a % of GDP was 0.26% in 1995, far below the OECD average of 1.46% 
(OECD, 1999b, p. 131). While no comprehensive data is available on R&D 
expenditure on biotechnology, it may be logical to assume that “if New Zealand is bad 
at doing R&D generally it would  [expect to be] a whole lot worse in the biotech 
area”56. 
 
One factor that would be expected to affect the level of R&D expenditure by industry 
is the tax and incentive regime. In a recent review of the evidence on the effects of 
fiscal incentives for R&D, Hall and Van Reenen (2000, p. 449) concluded that “in the 
                                                 
54 interview F, 8 April 2000 and interview E, 5 April 2000 
55 interview A, 11 April 2000 
56 interview B, 5 April 2000 
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current (imperfect) state of knowledge … a dollar in tax credit for R&D stimulates a 
dollar of additional R&D”.  
 
All OECD countries except New Zealand have special tax schemes for R&D 
expenditures such as immediate write-off and various types of tax credit, indeed New 
Zealand comes bottom of an OECD league table of the amount of tax subsidy for 
R&D (OECD, 1999b, p. 135). In New Zealand, private sector expenditure of one 
dollar costs companies $1.13 after tax and compliance are included. This compares to 
89 cents in Australia, 83 cents in Canada and 69 cents in Spain.  
 
It has also been suggested that differences in national tax regimes may significantly 
bias reported levels of R&D expenditure. The negative treatment of such expenditures 
in New Zealand encourages under-reporting57 while the favourable treatment in other 
countries encourages widespread over-reporting. 
 
Industry views appear to be somewhat polarised on whether the tax treatment of R&D 
spending has had a major effect on the level of expenditure in the private sector. Some 
large players saw this as a key influence: “the 150% tax rebate meant that you could 
do research for free in Australia and make money out of it … it was a pretty 
favourable regime – nothing like that here”58. Others were more sceptical: “I have not 
seen results that suggest support of R&D delvers real commercial benefits”59. 
 
Difficulties in obtaining venture capital may also constrain start-up or expanding 
biotech firms in New Zealand. Until recently no venture capital appeared to be 
available for biotechnology and companies relied on traditional methods of funding. 
Recently Morel Bank and Direct Capital partners have provided funds to the industry, 
the former being listed in the NZBA Biotechnology Directory (Hynes, 1999, p. 26). 
Auckland UniServices has also helped to establish a seed fund with starting capital of 
around NZ$15 million; it will establish in on-going research in the high-tech area, 
with the caveat that it should direct half its funding to matters arising out of the 
University of Auckland (Lee, 2000). 
 
5. Summary and Conclusions 
 
New Zealand has some ‘islands of excellence’ where world-leading biotechnology 
R&D is carried out and despite its small size has played a significant role in the 
biotechnology revolution. While most biotech activities build on existing strengths in 
primary industry (e.g. forestry, deer and sheep) there are also examples of innovative 
research in health and the creation of intellectual property. 
 
New Zealand’s gross expenditure on R&D and number of science graduates was the 
lowest in a group of 18 OECD countries. New Zealand’s small science base is heavily 
skewed towards certain areas e.g. biology, clinical medicine and agriculture. New 
Zealand scientists have a high productivity (measured by papers per scientist) but 
                                                 
57 see Rolleston (1999, p. 45) 
58 Interview B, 5 April, 2000 
59 Interview C, 30 March, 2000 
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New Zealand science is not highly cited internationally except in a handful of 
specialist areas e.g. pharmacology.  
 
The modern biotechnology ‘sector’ is small; consisting of around 40 organisations 
employing approximately 1250 people. A further 40 firms carry out various kinds of 
bio processing activity and employ over 500 people in ‘biotech based activities’. New 
Zealand’s rate of modern biotech patent applications is below average for the G7 and 
for a reference group of small developed OECD economies. Overall New Zealand 
ranks twelfth out of 18 with a patenting rate slightly above that found in France, 
Germany and Japan. However New Zealand’s performance is disappointing compared 
to other small countries with strong primary industries that it might hope to emulate 
e.g. Denmark, Netherlands and Australia.  
 
The factors that seem to have encouraged the emergence of world-leading research 
are diverse ranging from strong basic science in medical research and science push in 
sheep genomics, to industry pull in the case of forest biotechnology. Growth in these 
and other biotech-based sectors may be constrained by the poor performance of New 
Zealand’s National System of Innovation. The system is dominated by Crown 
Research Institutes and universities which rely on government for the majority of their 
funding. Leading edge work is carried out in certain areas, but this tends to involve 
links with a small number of organisations rather than strong connections to any wider 
system of innovation. There have been major changes to research, science and 
technology policy since the late 80’s, but it remains to be seen whether these will 
result in improved performance.  
 
There is a significant level of industry discontent with government policy and the 
framework conditions for innovation, particularly “the lack of a pro-business 
environment, national attitudes to entrepreneurs and risk takers and the regulatory 
framework which has made New Zealand an expensive country in which to do 
business”. On the positive side; research costs are estimated to be 40% below 
international levels. This and New Zealand’s rigorous border controls and relatively 
disease free status have been pushed heavily in an attempt to increase overseas 
funding of biotechnology activities in New Zealand.  
 
The New Zealand Government has not taken leadership in fostering innovation in the 
biotech sector. Indeed government and industry only seem to have taken a close 
interest in biotechnology in the last three to four years.  New Zealand has not made 
the kinds of large investment seen in Australia and some of its regional trading 
partners. Instead it has concentrated on science sector reforms and a free market 
oriented approach. New Zealand has the potential to demonstrate a new model for the 
development of a biotech industry based on comparative advantage in primary 
industry and some other niche areas. The jury is still out on whether New Zealand’s 
innovation environment will allow that potential to be achieved. 
 
 
 
 
 
 
 27
 
References 
 
AgResearch (1999) Annual Report 1999, New Zealand Pastoral Agricultural Research Institute, 
Hamilton. 
Alston, J. M., P. G. Pardey and V. H. Smith (1998) 'Financing Agricultural R&D in Rich Countries: 
What's Hapening and Why', Australian Journal of Agricultural and Resource Economics, 
Forthcoming  March, . 
Arundel, A. and A. Rose (1999) 'The Diffusion of Environmental Biotechnology in Canada: Adoption 
Strategies and Cost Offsets', Technovation, 19(9)  September, pp.551-560. 
Baker, E. (1998) 'Structural Biology - A Personal Account of its Development and Prospects in New 
Zealand', NZ Science Review, 55(3)  pp.11-16. 
Berridge, M. (1999) 'Effects of Science Restructuring Receive Little Attention', Laboratory News, 
June, . 
BIOTENZ (1998) BIOTENZ Promotional Brochure, Auckland. 
Birss, N. (2000, 25 April). Lincoln Scientists Develop Biosensor. The Christchurch Press, pp. 13. 
Bollard, A., D. Harper and M. Theron (1987) 'Research and Development in New Zealand: A Public 
Policy Framework',  
Breschi, S. and F. Malerba. (1997). Sectoral Innovation Systems: Technological Regimes, 
Schumpeterian Dynamics and Spatial Boundaries, Systems of Innovation: Technologies, 
Institutions and Organisations . London: Pinter. 
Bull, A., G. Holt and M. Lilly (1982) Biotechnology: International Trends and Perspectives, OECD, 
Paris. 
Carlsson, B. (ed) (1995) Technological Systems and Economic Performance: The Case of Factory 
Automation, Economics of Science, Technology and Innovation, Dordrecht: Kluwer. 
Carlsson, B. (ed) (1997) Technological Systems and Industrial Dynamics, Economics of Science, 
Technology and Innovation, Dordrecht: Kluwer. 
Carlsson, B. and R. Stankiewicz (1991) 'On the Nature, Function, and Composition of Technological 
Systems', Journal of Evolutionary Economics, 1(2)  pp.93-118. 
Cassie, F. (2000, April 14). University GM Research 'Can of Worms'. NZ Education Review, pp. 1. 
Clark, D. N., K. Pavlovich and B. Simpson (1999) 'The Horticulture and Food Research Institute of 
New Zealand Ltd',  
Cole, S. and T. J. Phelan (1999) 'The Scientific Productivity of Nations', Minerva, 37  pp.1-23. 
Dalziel, P. (1999) 'New Zealand's Economic Reform Programme was a Failure', July. 
Eliasson, G. and Å. Eliasson. (1997). The Pharmaceutical and Biotechnological Competence Bloc and 
the Development of Losec, Technological Systems and Industrial Dynamics (Vol. 10, ). 
Dordrecht: Kluwer. 
Engelbrecht, H.-J. and J. Darroch (1999) 'A Comparative Macro-Level Assessment of New Zealand's 
National Innovation System', Prometheus, 17(3)  September, pp.283-298. 
Environmental Risk Management Authority (1999) Briefing for the Incoming Government, ER-BR-01-
1 11/99, Environmental Risk Management Authority, Wellington. 
Ernst & Young (1999a) Australian Biotechnology Report 1999, Ernst & Young, Canberra. 
Ernst & Young (1999b) Bridging the Gap: Ernst & Young's 13th Biotechnology Industry Annual 
Report, Ernst & Young, Palo Alto, California. 
Farrell, R. (1999) Pacific GEM Proposal, University of Waikato, Hamilton. 
Foltz, J., B. Barham and K. Kim (2000) 'Universities and Agricultural Biotechnology Patents 
Production', Agribusiness, 16(1)  pp.82-95. 
Fontes, M. and A. Q. Novais (1998) 'The Conditions for the Development of a Biotechnology Industry 
in Portugal: The impact of Country Specific Factors', Technological Analysis & Strategic 
Management, 10(4)  . 
Foundation For Research Science and Technology (2000) Strategic Portfolio Outline: Advance 
Biological Enterprises, Foundation for Research, Science and Technology, Wellington. 
Fransman, M. and S. Tanaka. (1995). The Strengths and Weaknesses of the Japanese Innovation 
System in Biotechnology, The Biotechnology Revolution? (pp. 431-483). Oxford: Blackwell. 
Frater, P., G. Stuart, D. Rose and G. Andrews (1995) The New Zealand Innovation Environment, The 
Berl Foundation, Wellington. 
Freeman, C. (1987) Technology and Economic Performance: Lessons from Japan, Pinter. 
 
 28
Griliches, Z. (1990) 'Patent Statistics as Economic Indicators: A Survey', Journal of Economic 
Literature, 28(4)  December, pp.1661-1707. 
Hall, B. and J. V. Reenen (2000) 'How Effective are Fiscal Incentives for R&D? A Review of the 
Evidence', Research Policy, 29(4-5)  April, pp.449-469. 
Hazeldine, T. (1998) Taking New Zealand Seriously: The Economics of Decency, Harper Collins. 
Henderson, R., L. Orsenigo and G. P. Pisano. (1999). The Pharmaceutical Industry and the Revolution 
in Molecular Biology: Interactions Among Scientific Institutional, and Organisational Change, 
The Sources of Industrial Leadership (pp. 267-311): Cambridge University Press. 
Hynes, N. (1999) Strategic Alliances and the New Zealand Biotechnology Industry, Commerce 
Division, Lincoln University, Lincoln, New Zealand. 
Institute for Scientific Information (2000) National Science Indicators on Diskette, 1981-98, Institute 
for Scientific Information,  
Jacobsen, V. (1991) 'Contestable Funding: A New Deal for Research and Development in New 
Zealand', CIS Policy Monographs 19,  
Janszen, F. and G. Deganaars (1998) 'A Dynamic Analysis of the Relations Between the Structure and 
the Process of National Systems of Innovation Using Computer Simulation: The Case of the 
Dutch Biotechnological Sector', Research Policy, 27(1)  May, pp.37-54. 
Joly, P.-B. and M.-A. d. Looze (1996) 'An Analysis of Innovation Strategies and Industrial 
Differentiation Through Patent Applications: The Case of Plant Biotechnology', Research 
Policy, 25(7)  October, pp.1027-1045. 
Kennedy, M. J. and R. J. Davies (1994) The Impact of Biotechnology on New Zealand Industry 1984-
1994, SIR Publishing. 
Lee, Y. H. (2000, 6 March). New Fund Aims to Commercialise University Research. New Zealand 
Herald. 
Leech, W. (1999, ). Funding Partnership Links Bomac's Business Acumen, Massey Academia. Dairy 
Exporter, pp. 4. 
L'Huillier, P. (2000) Genetic Modification of Livestock for the Production of Therapeutics and 
Designer Foods, Dairy Farmers' Conference, Rotorua, New Zealand. 
Lundvall, B. (ed) (1992) National Systems of Innovation: Towards a Theory of Innovation and 
Interactive Learning, London: Pinter Publishers. 
Malo, S. and A. Geuna (1999) 'Science-Technology Linkages in an Emerging Research Platform: The 
Case of Combinatorial Chemistry and Biology', SPRU Electronic Working Paper No 37, 
August. 
Marshall, K. R. (2000) Biosciences: An Explanation of Why the New Zealand Dairy Industry is 
Investing in Research, Dairy Farmers' Conference, Rotorua, New Zealand. 
Massey, P. (1995) New Zealand: Market Liberalization in a Developed Economy, London: Macmillan. 
Mazoyer, P. (1999) A Study of the Innovation System for Biotechnology in New Zealand, Report No. 
1072, Ministry of Research, Science and Technology, Wellington. 
McKelvey, M. (1996) Evolutionary Innovations: The Business of Biotechnology, Oxford: Oxford 
University Press. 
McMillan, G. S., F. Narin and D. L. Deeds (2000) 'An Analysis of the Critical Role of Public Science 
in Innovation: the Case of Biotechnology', Research Policy, 29(1)  January, pp.1-8. 
Metcalfe, J. S. (1998) 'Innovation Systems and Endogenous Growth Theory',  
Ministry of Research Science and Technology (1999) Briefing for Incoming Minister of Research, 
Science and Technology, Ministry of Research, Science and Technology, Wellington. 
Momma, S. and M. Sharp (1999) 'Developments in New Biotechnology Firms in Germany', 
Technovation, 19(5)  February, pp.267-282. 
Nelson, R. R. (ed) (1993) National Innovation Systems: A Comparative Analysis, New York: Oxford 
University Press. 
New Zealand Trade Development Board (2000) Back to the Future New Zealand's Biotechnology 
Industry, New Zealand Trade Development Board, Auckland. 
NZBA (1999) 'King Salmon', New Zealand Biotechnology Association Newsletter, 43  . 
NZDB. (1999, 12 October). Dairy Industry Must Embrace Biotechnology. Press Release. 
NZPA. (2000a, 28 April). Dairy Board in Genetics Deals with US. The Dominion, pp. 6. 
NZPA. (2000b, ). NuFarm Buys up Biotech Company. The Dominion, pp. 20. 
OECD (1994) The Measurement of Scientific and Technological Activities. Using Patent Data as 
Science and Technology Inidcators: Patent Manual 1994, OECD, Paris. 
OECD (1997) Oslo Manual: Proposed Guidelines for Collecting and Interpreting Technological 
Innovation Data, Revised Edition (1997), OECD, Paris. 
 
 29
OECD (1999a) Modern Biotechnology and the OECD, OECD, Paris. 
OECD (1999b) OECD Science, Technology and Industry Scoreboard 1999 Benchmarking Knowledge-
Based Economies, OECD, Paris. 
Orsenigo, L. (1989) The Emergence of Biotechnology, New York: St Martin's Press. 
Pavitt, K. (1984) 'Sectoral Patterns of Technical Change: Towards a Taxonomy and a Theory', 
Research Policy, 13(6)  pp.343-373. 
Petersen, G. (1998) 'Science in New Zealand Beyond 2000. Have we Lost the Plot?', NZ Science 
Review, 55(3)  pp.4-10. 
Pockley, P. (1998) 'New Zealand puts its Science to Profit', Nature, 391  January 29, pp.426-427. 
Rickne, A. (1999). The Growth of New Technology-Based Firms: The Case of Biomaterials in 
Sweden, Massachusetts and Ohio, New Technological Systems in the Bio Industries: An 
International Study . 
Rolleston, W. (1999) Leveraging the Biology Revolution, Opportunities for Collaboration between 
Business, CRI's and Tertiary Institutions, Auckland: Royal Society of New Zealand. 
Royal Society of New Zealand (2000a) 'New Zealand Dairy Board Subsidiary Moves to Process 
Genetic Data', Royal Society Alert, 124  5 May, . 
Royal Society of New Zealand (2000b) 'Royal Commission on Genetic Modification', Royal Society 
Alert, 122  18 April 2000, pp.1-14. 
Saviotti, P. P. (1998). Industrial Structure and the Dynamics of Knowledge Generation in 
Biotechnology, Biotechnology and Competitive Advantage : Europe's Firms and the US 
Challenge (pp. 19-43). Cheltenham, UK: Edward Elgar. 
Simpson, B. and J. Craig (1997) 'A Policy for Science Innovation: The New Zealand Experience', 
Science and Public Policy, 24(2)  April, pp.70-78. 
Statistics New Zealand (2000) Biotechnology Survey 1998/99, Statistics New Zealand, Wellington. 
Tradenz (1994) 'The Foreign Exchange Earning Potential of the Pharmaceutical and Biotechnology 
Industry in New Zealand', New Zealand Biotechnology Association Newsletter, 25  December, 
pp.44-55. 
Upton, S. (1995) 'Contracting in the Science Sector: An Overview', Public Sector, 18(4)  December, 
pp.2-5. 
van Geenhuizen, M. (1999). How Small Biotechnology Firms Survive in the Dutch Pharmaceutical 
Industry: An Exploratory Analysis, New Technology-based Firms in the 1990s (Vol. Volume 
VI, ). Amsterdam: Pergamon. 
Walker, P. and J. Liu (1998) Baseline Indicators for Measuring Progress Towards the Goals of RS&T: 
2010, Ministry of Research Science and Technology,, Wellington. 
Winsley, P., P. Couchman and D. Gilbertson (1998) 'Future Developments for New Zealand's Science 
and Technology System', Prometheus, 16(1)  pp.57-68. 
Winsley, P. and L. Hammond (1997) 'Policies for Transforming the Science and Technology System in 
New Zealand 1988-1997', Prometheus, 15(2)  pp.267-278. 
Zucker, L. G. and M. R. Darby (1996) 'Star Scientists and Institutional Transformation: Patterns of 
Invention and Innovation in the Formation of the Biotechnology Industry', Proceedings of the 
National Academy of Sciences, 93(23)  November 12, pp.12709-12716. 
